Characterization and outcomes of 414 patients with primary SS who developed hematological malignancies

Gabriela Hernández-Molina[1], Belchin Kostov[2-3], Pilar Brito-Zerón[4], Arjan Vissink[5], Thomas Mandl[6] , Anneline C Hinrichs[7], Lucca Quartuccio[8], Chiara Baldini[9], Raphael Seror[10], Antonia Szántó[11], David Isenberg[12], Roberto Gerli[13], Gunnel Nordmark[14], Astrid Rasmussen[15], Roser Solans[16], Benedikt Hofauer[17],Damien Sène[18], Sandra G. Pasoto[19], Maureen Rischmueller[20], Sonja Paprovnik[21], Tamer A Gheita[22], Debashish Danda[23], Berkan Armağan[24], Yasunori Suzuki[25], Valeria Valim[26], Valerie Devauchelle-Pensec[27], Soledad Retamozo[28], Marika Kvarnstrom[29], Agata Sebastian[30], Fabiola Atzeni[31], Roberto Giacomelli[32], Steven E. Carsons[33],Seung-Ki Kwok[34], Hideki Nakamura[35], Virginia Fernandes Moça Trevisani[36], Alejandra Flores-Chávez[37,38], Xavier Mariette[10], and Manuel Ramos-Casals[38-39] and the Sjögren Big Data Consortium*.

[1]Immunology and Rheumatology Department. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Mexico City, Mexico.
[2]Primary Healthcare Transversal Research Group, IDIBAPS, Barcelona, Spain.
[3]UPC, Barcelona, Spain
[4]Department of Medicine, Autoimmune Diseases Unit, Hospital CIMA- Sanitas, Barcelona, Spain.
[5]Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
[6]Department of Clinical Sciences Malmö, Division of Rheumatology, Lund University, Malmö, Sweden.
[7]Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
[8]Clinic of Rheumatology. Department of Medicine (DAME), University of Udine, ASU FC, Udine, Italy
[9]Rheumatology Unit, University of Pisa, Pisa, Italy.
[10]Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, Université Paris-Saclay, INSERM, Paris,France.
[11] Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Hungary.
[12]Centre for Rheumatology, Division of Medicine, University College London, UK
[13]Rheumatology Unit, Department of Medicine & Surgery, University of Perugia.
[14] Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
[15]Genes and Human Disease Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
[16]Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain
[17] Otorhinolaryngology / Head and Neck Surgery, Klinikum rechts der Isar, Technical University of Munich, Germany.

[18]Université de Paris, Departement of Internal Medicine, Hôpital Lariboisière, Assistance Publique- Hôpitaux de Paris, Paris, France.
[19]Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
[20]Department of Rheumatology, The Queen Elizabeth Hospital, Discipline of Medicine, University of Adelaide, South Australia.
[21]Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia.
[22]Rheumatology Department, Kasr Al Ainy School of Medicine, Cairo University, Egypt.
[23] Department of Clinical Immunology & Rheumatology, Christian Medical College & Hospital, Vellore, India.
[24]Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey.
[25]Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
[26]Department of Medicine, Federal University of Espírito Santo, Vitória, Brazil.
[27]Rheumatology Department, Brest University Hospital, Brest, France.
[28]Rheumatology Department, Hospital Universitari Parc Taulí, Sabadell, Barcelona, Spain. Instituto Modelo de Cardiología Privado SRL, Córdoba, Argentina. Instituto Universitario de Ciencias Biomédicas de Córdoba (IUCBC), Córdoba- Argentina.
[29] Division of Rheumatology, Department of Medicine, Karolinska Institutet. Karolinska University Hospital, Stockholm, Sweden and Academic Specialist Center, Center for Rheumatology, Stockholm Health Services, Region Stockholm, Sweden.
[30]Department of Rheumatology and Internal Medicine, Wroclaw Medical University Wroclaw,Poland.
[31]IRCCS Galeazzi Orthopaedic Institute, Milan and Rheumatology Unit, University of Messina, Italy.
[32]Department of clinical immunology and Rheumatology. University of Rome "Campus Biomedico", school of Medicine, Rome, Italy.
[33]Division of Rheumatology, Allergy and Immunology NYU Long Island School of Medicine, Mineola, NY, USA.
[34]Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
[35]Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.
[36]Federal University of São Paulo, Sao Paulo, Brazil.
[37]CONACYT, Mexico.
[38]Department of Autoimmune Diseases, ICMiD, Barcelona, Spain.
[39]Department of Medicine, University of Barcelona, Hospital Clinic, Barcelona, Spain.

* The members of the EULAR-SS Task Force Big Data Consortium are listed in the acknowledgment section.

Address reprint requests to:
Dr Manuel Ramos-Casals
Servei de Malalties Autoimmunes Sistèmiques, Hospital Clínic,
C/Villarroel, 170, 08036-Barcelona, Spain.
ORCID 0000-0001-5709-6734
Phone: 34-93-2275774.
FAX: 34-93-2271707.
e-mail: mramos@clinic.ub.es

ABSTRACT

Objective. To characterize patients with primary Sjögren's syndrome (PSS) with hematological malignancy (mainly lymphoma), and to analyze how the malignancy subtype, the organ primarily involved and the timing of diagnosis may influence the clinical presentation and outcome.

Methods. Retrospective cohort study that included 414 patients with a hematological malignancy and 742 control age-sex-disease duration matched patients across the Big Data Sjögren Project Consortium .

Results. Most of the patients (91%) had B–cell lymphoma, being MALT the most prevalent (47.5%) and with the best response (Complete response (CR) >90%). Patients with primary salivary gland involvement (40%) were younger, with more MALT subtype , higher CR rate and lower mortality. There were differences among the main lymphoma subtypes (MALT, nodal MZL, DLBCL, CLL/SLL and FL) regarding to clinical presentation and outcomes. In 43 patients, hematological malignancy preceded the SS diagnosis in at least one year; being these patients older, less frequently diagnosed with B-cell malignancy, with a higher CR rate and lower mortality. ESSDAI scores did not differ among treatment response groups and survival status. We confirmed some clinical and serological variables as lymphoma risk factors.

Conclusion. This is the largest cohort of PSS with hematological malignancy. Hematological malignancy expanded well beyond parotid MALT lymphoma. Their outcome is driven by malignancy subtype, primary involved organ and presentation time regarding SS diagnosis. A bidirectional multidisciplinary follow-up of patients with SS and hematological malignancy is highly recommended.

KEYWORDS. Sjögren syndrome, hematological malignancy, lymphoproliferative disease, lymphoma, MALT

Key messages

- Hematological malignancy in SS expands well beyond parotid MALT lymphoma.
- Their outcome is driven by the neoplasia subtype, primary involved organ and presentation time.
- In 10% of the patients, the hematological malignancy might precede the diagnosis of SS.

INTRODUCTION

Patients with autoimmune diseases have a high risk of developing hematological malignancies, especially lymphomas [1]. Although the pathophysiology of this association is unknown, it is probably due to the interplay of individual genetic and environmental factors triggering a chronic inflammatory scenario characterized by persistent B-cell activation [2-3]. Indeed, patients with primary Sjogren's syndrome have a 10- to 40-fold higher risk of developing lymphoma than healthy individuals [4]. The pathogenesis of SS is characterized by a chronic lymphocytic infiltration especially centered in the exocrine glands but also encompassing extraglandular tissues [5]. A sustained stimulation of B cells by autoantigens and immune complexes abnormally expressed in salivary and lachrymal glands, has been postulated as an underlying pathogenic scenario that may predispose for development of malignancy. A multi-step pathogenic process follows, involving pro-oncogenic factors that could favor the transition from a benign B-cell process to a malignant proliferation [5].

Despite the evident association between hematological malignancy and primary SS we still have a limited view of that association. The number of cases included in the main studies are often small and collected from single centers, and overwhelmingly centered on B-cell lymphomas. Focusing on the main studies published in the last 20 years including patients with primary SS, most reported 30-50 patients and only 3 described around 100 patients. [6-20] [**Supplementary Table S1**].

In this study, we describe the main features and risk factors of 414 patients with primary SS who developed overall hematological malignancies, including a specific analysis of how certain features (lymphoma subtypes, organ primarily involved by the malignancy, systemic SS activity and timing of diagnosis) may influence the clinical presentation patterns and outcomes of the malignancy.

PATIENTS AND METHODS

The Big Data Sjögren Project Consortium is an international, multicentre registry established in 2014 to take a “high-definition” picture of the main features of primary SS using worldwide data-sharing cooperative merging of pre-existing clinical databases from leading centers in SS from the five continents. The centers share a harmonized data infrastructure and conduct cooperative online efforts in order to refine already-collected data in each center [21]. By January 2021, the database included 11,966 patients fulfilling the 2002 AECG classification criteria [22] and/or the 2016 ACR/EULAR classification criteria [23]. Systemic involvement was retrospectively scored using the ESSDAI [24]. The study was approved by the Ethics Committee of the Coordinating Centre (Hospital Clinic, Barcelona, Spain, registry HCB/2015/0869).

Hematological malignancy data

Hematological malignancies were diagnosed according to the World Health Organization (WHO) classifications [25-26]. We retrospectively collected: constitutional symptoms at diagnosis (fever, sweats, and unexplained weight loss), site of confirmatory biopsy, bone marrow involvement, WHO classification, treatment, treatment response, relapse, time of follow-up and death. For extranodal lymphomas, the primary site of malignancy involvement was defined as the clinically dominant extranodal component, which requires diagnostic investigation and to which primary treatment must often be directed [27]. In all cases, the diagnosis was confirmed by a hematopathologist, and follow-up was provided by the multidisciplinary care team.

Statistical analysis

Descriptive data are presented as mean and standard deviation (SD) for continuous variables and numbers and percentages (%) for categorical variables. We used Chi-square test and t-test, according the type of variable. Logistic multivariate regression models adjusting for age at diagnosis and sex were constructed to analyze independent factors associated with mature B cell malignancy subtypes, salivary

gland lymphoma, and timing of diagnosis of malignancy. We reported Odds ratios (OR) and 95% confidence intervals (95% CI). Time-to-event analyses for death are presented as Kaplan-Meier curves. The Log-rank test was used to compare the survival curves. A two-tailed $P<0.05$ was considered statistically significant. All analyses were conducted using the R V.3.5.0 for Windows statistical software package.

The variables selected for analyzing their potential influence on the clinical presentation patterns and outcomes of the malignancy were categorized as follows:

1) Lymphoma subtypes: extranodal marginal zone lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT lymphoma), nodal MZL, diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL).

2) Primary extranodal site: salivary glands vs those arising in other sites (when patients had both types of involvement, they were included in the salivary gland group)

3) Time of diagnosis of hematologic malignancy: prior to SS (diagnosed > 1 year prior to SS diagnosis) or concurrent with/after SS diagnosis (diagnosed within < 1 year of SS diagnosis, concomitantly or during the follow-up of patients already diagnosed with SS).

4) ESSDAI as predictor of therapeutic response and lymphoma survival: comparison of the mean ESSDAI score measured before starting lymphoma treatment (at the time of diagnosis of hematological malignancy in patients already diagnosed with SS), stratified according to the therapeutic response (complete, partial, no response) and the survival (yes, no) and adjusted according to the type of lymphoma and Ann Arbor Staging Classification.

5) Risk factors: baseline features at the time of SS diagnosis were compared in patients with and without hematological malignancy following an age, sex and disease duration-matched 1:2 case-control design (excluding those patients diagnosed with hematological malignancy prior SS).

RESULTS

Among the 11,966 patients with primary SS included in the Registry, 463 had a hematological malignancy. Of these patients, 49 were excluded because the diagnosis was not confirmed by a hematopathologist and/or fulfillment of the WHO classification was not available. Therefore, 414 patients (3.46%, CI 95% 3.13%-3.79%) were finally included (355 women, mean age of 57.21 years); in 258 cases, the malignancy was diagnosed one year after the SS diagnosis (67 of whom were incident cases).**Table 1** summarizes the main features related to hematological malignancies and **Supplementary Table S2**, the main SS-related features at the time of primary SS diagnosis.

Characterization of hematological malignancies

The clinical presentation of the hematological malignancy included glandular enlargement (n=176, 45.4%), constitutional symptomatology (n=126, 34%) and peripheral lymphadenopathies (n=109, 29.4%). Hematological malignancy was occasionally diagnosed in asymptomatic patients, either by an abnormal peripheral blood count (n=31, 8.3%), incidental detection in imaging studies (n=2, 0.5%), or by salivary gland biopsies (n=6, 3 after parotid biopsy and 3 after minor salivary gland biopsy).

According to the WHO classification, 376 (91%) patients were classified as having mature B cell malignancy, followed by myeloid neoplasia/acute leukemias (n=20,5%), Hodgkin lymphoma (n=10, 2%) and mature T and NK malignancy (n=8, 2%) [**Table 1**]. Among mature B cell malignancies, nearly half the cases were diagnosed with MALT lymphoma (n=197, 47.5%), followed by DLBCL (n=67, 16.2%), nodal MZL lymphoma (n= 29, 7%), CLL/SLL (n=19, 4.5%) and follicular lymphoma (n=17, 4.1%) [**Table 1**]. We have data about the site of confirmatory biopsy in 386 (93.2%) patients, with the parotid (n=147, 36%) and lymph nodes (n=92, 24%) being the most common organs biopsied [**Table 1**]. Other exocrine glands were rarely affected (lachrymal glands in 8 patients, submandibular glands in 8 patients). **Figure 1** shows the distribution of the primary extranodal sites, and 7 patients had more than one extranodal site affected (mean ESSDAI score of 17.1) including the parotid glands

(n=6), lungs (n=5), and liver, stomach or lachrymal glands (one case each, respectively). Information about Ann Arbor Staging Classification of lymphoma was available in 320 patients: 21 (6.6%) were classified as stage I, 166 (51.9%) as stage II, 37 (11.5%) as stage III and 96 (30%) as stage IV.

Among 281 patients with available data about therapeutic response **(Supplementary Figure S1)**, we observed complete response (CR) in 225 (80%), partial response (PR) in 38 (13.5%), and no response (NR) in xx (xx%) patients. R-CHOP was the immunochemotherapy regimen most commonly used; there was a trend toward a better survival rate in comparison with patients treated only with chemotherapy (CHOP), although the difference was not statistically significant (**Supplementary Figure S2**). H. pylori was tested in 10 out of the 13 patients with gastrointestinal MALT lymphoma, of whom 7 were positive and received eradication treatment. Relapses occurred in 90 (34.2%) patients who showed a complete/partial response to the first-line therapeutic approach. Among them, 14 showed a transition to a different WHO subtype, overwhelmingly as a progression to high-grade lymphomas (DLBCL 10 patients, peripheral T-cell lymphoma 2 patients).

Information about the follow-up of hematological malignancy was available in 365 patients who were followed for a mean time of 8.06 years [**Supplementary Figure S1**]. Forty-seven (12.9%) patients died, mainly due to malignancy progression (n=20, 51%) and infections (n=12, 31%). **Figure 2A** shows the Kaplan-Meier curve of the cumulative survival free of death. The 1-year, 2-year and 5-year survival rates were 93.2%, 90.0% and 86.5%, respectively.

Specific substudies

1. Lymphoma subtypes.

Table 2 summarizes the differences between the main lymphoma subtypes (MALT lymphoma, nodal MZL, DLBCL, CLL/SLL and FL). There were significant differences with respect to the age at diagnosis (younger in MALT, older in CL/SLL, p=0.002), pattern of clinical presentation (glandular enlargement in MALT lymphoma, peripheral lymphadenopathy in nodal MZL and FL, constitutional symptoms in DLBCL, incidental diagnosis in CLL/SLL), therapeutic response (higher in MALT

lymphoma, lower in DLBCL) and survival (better in MALT lymphoma, nodal MZL and FL, worse in DLBCL). **Figure 2B** shows the Kaplan-Meier curves of the cumulative survival among patients with the main lymphoma subtypes.

2. Salivary vs extrasalivary lymphoma.

Patients classified as having lymphoma arising in salivary glands were diagnosed at a younger age, had a higher frequency of MALT lymphoma and a lower frequency of DLBCL, a higher rate of CR and a lower mortality rate in comparison with patients with extrasalivary lymphoma [**Table 3 se puede pasar a suplementaria si es necesario**]. **Figure 2C** shows the Kaplan-Meier curves of the cumulative survival of patients with salivary and extrasalivary lymphoma.

3. Hematological malignancy preceding SS diagnosis.

In 43 (10%) patients, hematological malignancy was diagnosed at least one year before the diagnosis of SS. These patients were diagnosed with the hematological malignancy at an older age, were less frequently diagnosed with a B-cell malignancy, had a higher rate of CR and a lower mortality rate in comparison with patients where the malignancy was diagnosed concomitantly or after SS diagnosis [**Table 4]**. **Figure 2D** shows the Kaplan-Meier curves of the cumulative survival of patients diagnosed with malignancy before or after the SS diagnosis.

4. Systemic SS activity

The mean of the total ESSDAI scores was similar among the lymphoma subgroups **(Table 2)**, while for the organ-specific domains, patients diagnosed with MALT are those with the higher rate of activity in the glandular domain while those diagnosed with DLBCL had the higher rate of activity in the constitutional domain. After excluding the domains overlapped with the clinical and laboratory manifestations related to hematological malignancies, there were 31 patients who had systemic activity at the time of malignancy diagnosis in the cutaneous (n=21), neurological (n=15), pulmonary (n=4) and renal (n=2) ESSDAI domains. In these patients, systemic activity was completely resolved in 21 (68%), partially resolved in 6 (19%)

and non-resolved in 4 (13%) patients after receiving specific treatment for malignancy. The pre-therapeutic total mean ESSDAI scores were stratified according to the therapeutic response achieved (19.1 ± 6.3 in patients with CR, 18.1 ± 5.1 in those with PR and 17.8 ± 6.7 in non-responders, p=0.47) and the survival (16.8 ± 5.2 in patients who died vs 18.4 ± 5.9 in survivors, unadjusted p value of 0.052, adjusted according to the type of lymphoma and Ann Arbor classification, p=0.122).

5. Risk factors of hematological malignancy

The main baseline features identified at the time of SS diagnosis as the strongest risk factors associated with the development of hematological malignancy (p<0.001) included abnormal results in the diagnostic oral tests, immunological parameters (ANA, RF, anti-Ro, anti-La, monoclonal cryoglobulins, low C3 and low C4 values) and a higher level of baseline systemic activity both total (ESSDAI and DAS) and organ-specific (constitutional, lymphadenopathy, glandular, haematological and biological domains) in comparison with the age, sex and disease duration-matched controls without hematological malignancy (**Table 5**).

DISCUSSION

The SIR for overall hematologic malignancy is 11-fold higher in primary SS than in the general population [15]. Specifically, primary SS patients have an increased risk of lymphoma [28-31] that is driven by individual epidemiological, clinical, immunological and histological factors [6-7,11-12,14-15,17,32-34]. We present the largest reported cohort of primary SS patients complicated with hematological malignancies, 91% of which are B-cell lymphomas, a similar rate as reported in smaller studies [6,9,16,20] **[Suppl Table S1]**. Mature T malignancy accounted for only 2% of hematological malignancies, a figure substantially lower than general population (10–15%) [35], and which highlights the overwhelming predominance of B-cell malignancy in SS.

Among B cell lymphoma in the general population [36], the 3 most frequent subtypes are DLBCL (40%), FL (20%) and MZL (7%) [26,37-38]. In contrast, in our patients, the frequencies were 15% for DLBCL, 4% for FL and 54% for MZL. An international consortium estimated a 30-fold increased risk for MZL, a 9-fold increased risk for DBCL and a 4-fold increased risk for FL in primary SS [34]. The predominance of MZL in primary SS (overwhelmingly represented by the MALT subtype) is not surprising considering that it is a group of low-grade (indolent) extranodal B-cell lymphoma that arises in areas of preexisting chronic lymphoid proliferation in mucosal sites [39]. All previous studies in primary SS have reported a similar distribution (MALT as the most frequent subtype, DLBCL the second most frequent) **[Suppl Table S1].**

A key objective of our study was to characterize the different B-cell lymphoma subtypes. Previously, only a few studies have reported data comparing MALT lymphoma and DLBCL [14,20,40-41]. We observed substantial differences in the ratio of affected women (18:1 for CLL/SLL, around only 3:1 for FL) and in the age at malignancy diagnosis (the youngest in MALT lymphoma and the oldest in CLL/SLL patients). There was also a differential clinical presentation of malignancy, consisting of glandular enlargement in MALT lymphoma, peripheral lymphadenopathy in nodal MZL and FL, constitutional symptoms in DLBCL, and incidental diagnosis in

CLL/SLL. The therapeutic response and the survival rates were also different (higher in MALT lymphoma, lower in DLBCL).

We confirmed salivary glands as the major primary site of hematologic malignancy in primary SS (around 40% of cases), supporting a link with the pathogenesis of the disease [5]. The distribution of the different B-cell malignancy subtypes in salivary gland in primary SS was also clearly different from general population given the predominant role of MALT lymphoma, in 85% of our cases. In contrast, in non-SS population, the proportion of each lymphoma subgroup in the parotid gland is similar (about 23-27%) [42]. [**Supplementary Figure S3**]. The reason for the overwhelming involvement of the parotid glands over the lachrymal glands is unknown. One possibility might be a change in the oral microbiota due to the chronic autoimmune damage or a higher amount of immune complexes in saliva.

We also reported lymphomas in other extranodal sites, including the digestive system in 7.4% (mainly stomach), ENT sites in 3.2% (mainly palate) and the respiratory system in 2.7% (mainly lung), a different scenario to that reported in non-SS population, in which stomach (30-40%) and the skin [37] are the main sites. The higher mortality rate of patients with extra-salivary lymphoma could be attributed to the predominance of DLBCL, which has the highest mortality rate among the different lymphoma subtypes in our SS cohort (30%), although this rate is similar to that reported in middle-aged persons diagnosed with DLBCL unrelated to SS (12 to 39%) [43].

Hematological malignancy was reported at least one year before the SS diagnosis in 10% of our patients. One might think that these are patients in whom SS was in a quiescent stage for years until the neoplasm appeared, but their mean age is almost 10 years older than the age at which the malignancy was diagnosed in patients already diagnosed with SS. Although this group was less frequently diagnosed with B-cell malignancy; MALT lymphoma remained the most prevalent subtype. And it is probable that their lower mortality may be underestimated, as some patients may have died before the SS diagnosis [**Supplementary Figure S4**]. Among the Swedish patient register, 18 of 107 lymphoma cases were diagnosed before or within

6 months of primary SS diagnosis. These patients were more often men, had lymphadenopathy and salivary gland MALT lymphoma [19].

Regarding the association between systemic activity (ESSDAI scores) and lymphoma in primary SS patients, we found an expected correlation with some specific lymphoma subtypes (higher constitutional activity in DLBCL and higher glandular activity in MALT lymphoma), demonstrating the great overlap between the key lymphoma-related clinical and laboratory features and most of the ESSDAI domains. The main example is the maximum score achieved in the lymphadenopathy domain by all patients diagnosed with malignancy (score of 12), followed by the evident overlap in most of the other ESSDAI domains including constitutional (fever, weight loss), glandular (parotid enlargement), hematological (cytopenias) and biological (hypergammaglobulinemia, monoclonal bands). Therefore, in more than 90% of our cases, lymphoma features contributed to the 75-100% of the total ESSDAI score measured at the time of lymphoma diagnosis. In addition to the undeniable clinical and laboratory overlap, there is an additional therapeutic confounder effect since the key therapeutic drugs used for treating lymphoma (corticosteroids, cyclophosphamide, rituximab) are agents also extremely effective against systemic disease. In fact, we found that pre-therapeutic ESSDAI score was not a predictive factor for either a better lymphoma therapeutic response (event-free) or for a better survival. Due to the multiple confounding factors between lymphoma and systemic disease, ESSDAI cannot be considered as an independent variable in order to calculate its association with event free and overall survival of patients with Sjögren.

Some limitations must be mentioned. First, because of our retrospective design, we did not have complete information in all patients, and the diagnostic approach and treatment options may have changed over the years. Nonetheless, the quality of our information was carefully recorded and provided by expert centers. Second, although 252 of our patients were already included in previously published studies, none of those studies specifically characterized lymphoma subtypes (asegurar, creo que hay estudios de autores com Solans-Laqué 2011 que han analizado específicamente casos de linfoma) Third, the predominant presence of European

patients could limit the external validity of our study. Finally, since the participant centers are mainly tertiary university centers, the magnitude of the selection bias may vary between countries.

Summing up, this study is the largest on hematological malignancy in patients with primary SS. The specific pathogenesis of this disease may explain the very specific profile of hematological malignancies, overwhelmingly dominated by B-cell origin, especially MALT, with the salivary glands being the primary site of involvement. We also confirmed the predictive role of immunological parameters and systemic disease reported in previous smaller studies (6-7,11-12,14-15,17,32-34), suggesting that an enhanced baseline polyclonal Ig expansion and monoclonal gammopathy confers a higher risk of developing hematological malignancies. The histopathological scenario was linked to the overall good prognosis with a 5-year survival rate higher than 80%. It is important to highlight that histopathological findings in primary SS expand well beyond parotid MALT lymphoma. In addition, one in ten primary SS patients will have a hematological malignancy diagnosed at least one year before the SS diagnosis; therefore, hematologists should keep this in mind to recognize coexisting SS. Our findings converge in one direction; to ensure the mandatory and bidirectional multidisciplinary follow-up of both patients with primary SS and those with hematological malignancy.

Funding statement

No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

Conflicts of interest

The authors declare that they have no competing interests.

Data Availability Statement

The data underlying this article will be shared at reasonable request to the corresponding author.

ACKNOWLEDGMENTS

Members of the Sjögren Big Data Consortium P. Brito-Zerón, A. Flores-Chávez, M. Ramos-Casals (Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Department of Autoimmune Diseases, ICMiD, University of Barcelona, Hospital Clínic, Barcelona, Spain); I.F. Horvath, A. Szántó, T. Tarr (Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Hungary); F. Ng (Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK); A. Rasmussen, K. Sivils (Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA); X. Dong, Z. Yan (Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China); X. Li, B. Xu (Department of Rheumatology and Immunology, Anhui Provincial Hospital, China); C. Baldini, S. Bombardieri (Rheumatology Unit, University of Pisa, Italy); T. Mandl, P. Olsson (Department of Rheumatology, Malmö University Hospital, Lund University, Sweden); R. Priori, F. Giardina, R. Izzo (Department of Internal Medicine and Medical Specialties, Rheumatology Clinic, Sapienz. University of Rome, Italy); R. Seror, X. Mariette (Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France); J.E. Gottenberg (Department of Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France); A.A. Kruize, A. Hinrichs (Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, The Netherlands); H. Bootsma (Department of Rheumatology & Clinical Immunology, University of Groningen, University Medical Centre Groningen, the Netherlands); A. Vissink (Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Centre Groningen, The Netherlands); D. Danda, P. Sandhya (Department of Clinical Immunology & Rheumatology, Christian Medical

College & Hospital, Vellore, India); G. Hernandez-Molina, J. Sánchez-Guerrero (Immunology and Rheumatology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico); B. Armagan, L. Kilic, U. Kalyoncu (Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey); L. Quartuccio (Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, University of Udine, Italy); S. Gandolfo, S De Vita (Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy); S. Praprotnik (Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia); A. Sebastian, P. Wiland (Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland); R. Gerli, E. Bartoloni (Rheumatology Unit, Department of Medicine, University of Perugia, Italy); S-K. Kwok, S-H. Park (Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea); M. Kvarnstrom, M. Wahren-Herlenius (Department of Medicine, Solna, Division of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden); M. Rischmueller, S. Downie-Doyle (Department of Rheumatology, The Queen Elizabeth Hospital, University of Adelaide, South Australia); R. Solans(Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain); D. Sene (Service de Médecine Interne 2, Hôpital Lariboisière, Université Paris VII, Assistance Publique-Hôpitaux de Paris 2, Paris, France); S.G. Pasoto (Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil); Y. Suzuki, M. Kawano (Division of Rheumatology , Kanazawa University Hospital , Kanazawa , Ishikawa , Japan); D.A. Isenberg (Centre for Rheumatology, Division of Medicine , University College London, UK); G. Nordmark (Rheumatology, Department of Medical Sciences, Uppsala University, Sweden); V. Valim (Department of Medicine, Federal University of Espírito Santo, Vitória, Brazil); H. Nakamura, T. Shimizu, S.-Y. Nishihata (Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan); T. Nakamura, Y. Takagi (Department of Radiology and Cancer Biology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan); V. Moça Trevisano (Federal University of São Paulo, Brazil); S. Retamozo (Instituto Modelo de Cardiología Privado SRL, Córdoba, and Instituto Universitario de Ciencias Biomédicas de Córdoba (IUCBC), Argentina); B. Hofauer, A. Knopf (Otorhinolaryngology/Head and Neck Surgery, Technical University Munich, Germany); G. Fraile (Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain); R. Giacomelli, (University of Rome "Campus Biomedico"- School of Medicine, Rome, Italy); V. Devauchelle-Pensec, A. Saraux (Rheumatology Department, Brest University, INSERM 1227, Brest, France); M. Bombardieri, E. Astorri (Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, UK); F. Atzeni (IRCCS Galeazzi Orthopaedic Institute, Milan, and Rheumatology Unit, University of Messina, Italy); D. Hammenfors, J.G. Brun (Department of Rheumatology, Haukeland University Hospital, Bergen, Norway); S.E. Carsons (Division of Rheumatology, Allergy and Immunology Winthrop-University Hospital, Stony Brook University School of Medicine, Mineola, NY, USA); B. Maure Noia, A.B. Argibay Filgueira (Department of Autoimmune Diseases,

Complexo Hospitalario Universitario de Vigo, Spain); T.A. Gheita, (Rheumatology Department, Kasr Al Ainy School of Medicine, Cairo University, Egypt); I. Sánchez Berná (Department of Internal Medicine, Hospital Rey Juan Carlos de Móstoles, Madrid, Spain); M. López Dupla, R. Alberto Rojas, A.M. Febrer Nafria (Department of Internal Medicine, Hospital Joan XXIII, Tarragona, Spain); J. Morel (Department of Rheumatology, Teaching Hospital and University of Montpellier, France); E. Fonseca Aizpuru, S. Santos Seoane (Department of Internal Medicine, Hospital de Cabueñes, Gijón, Spain); P. Brito-Zerón, C. Morcillo (Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona, Spain); S. Melchor Díaz, P. Carreira (Department of Rheumatology, Hospital 12 de Octubre, Madrid, Spain); C. Vollenveider (German Hospital, Buenos Aires, Argentina); M. Vázquez (Department of Rheumatology, Hospital de Clínicas, Asunción, Paraguay); P. Ericka Díaz Cuiza, B.E. Herrera (Departamento de Reumatología del Seguro Social Universitario y Consultorio Privado de Reumatología, Sucre, Bolivia); S. Andrea Consani, A. Comotto (Department of Internal Medicine, Hospital Maciel, Monteviedo, Uruguay); B. de Miguel Campo (Department of Internal Medicine, Hospital 12 de Octubre, Madrid, Spain); B. Kostov, A. Sisó-Almirall (Primary Healthcare Transversal Research Group, IDIBAPS, Primary Care Centre Les Corts, CAPSBE, Barcelona, Spain); B. Kostov, N. Acar-Denizli (Department of Statistics and Operations Research, Universitat Politècnica de Catalunya, Barcelona, Spain).

REFERENCES

1.- Hemminki K, Huang W, Sundquist J, Sundquist K, Ji J . Autoimmune diseases and hematological malignancies: Exploring the underlying mechanisms from epidemiological evidence. *Semin Cancer Biol* 2020;64:114-121.

2.- Nourelding HA, Nour-Eldine W, Hodroj MH, Noureldine MHA, Taher A, Uthman I. Hematological malignancies in connective tissue diseases. *Lupus* 2020;29:225-235.

3.- Azrielant S, Tiosano W, Watad A, Mahroum N, Whitby A, Comanshter D , et al. Correlation between systemic lupus erythematosus and malignancies: a cross sectional population-based study. *Immunol Res* 2017;65:464-9.

4.- Zintzaras E, Voulgarelis M, Moutsopoulos H. The risk of lymphoma development in autoimmune diseases: a meta-analysis. *Arch Intern Med* 2005;165:2337-2344.

5.- Retomozo S, Brito-Zerón P, Ramos-Casals M. Prognostic markers of lymphoma development in primary Sjögren's syndrome*. Lupus* 2019;28:923-936.

6.-Ioannidis J, Vassiliou V, Moutsopoulos H. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. *Arthritis Rheum* 2002;46: 741-7.

7.- Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos H. Hematologic manifestations and predictors of lymphoma development in primary Sjögren's syndrome: Clinical and pathophysiologic aspects. *Medicine (Baltimore)* 2009; 88:284-293.

8.- Pollard R, Pijpe J, Bootsma H, Spijkervet F, Kluin P, Roodenburg J, et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjögren's syndrome: a retrospective clinical study. *J Rheumatology* 2011;38:2198-2208.

9.-Voulgarelis M, Ziakas PD, Papagergiou A, Baimpa E, Tzioufas A, Moutsopoulos H. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren's syndrome. *Medicine (Baltimore)* 2012; 91:1-9.

10.- Weng MY, Huang YT, Liu MF, Lu T. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjögren's syndrome in Taiwan. *Ann Rheum Dis* 2012; 71:524-57.

11.- Quartuccio L, Isola M, Baldini C, Priori R, Bartoloni B, Carubbi F, et al. Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions. Results of a multicenter study. *J Autoimmun* 2014;51:75-80.

12.- Baldini C, Pepe P, Quartuccio L, Priori R, Bartoloni E, Alunno A et al. Primary Sjögren's syndrome as a multi-organ disease: Impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. *Rheumatology* 2014;53:839-844.

13.- Nocturne G, Virone A, Wan-Fai Ng, Le Guern V, Hachulla E, Cornec D, et al. Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome. *Arthritis Rheumatol* 2016;68:977-985.

14.- Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk of lymphoma development in Sjögren' syndrome: An easy tool for clinical use. *Medicine* 2016;95(25):e3766.

15.- Brito-Zerón P, Kostov B, Fraile G, Caravia-Durán D, Maure B, Rascón FJ, et al. SS Study Group GEAS_SEMI. Characterization and risk estimate of cancer in patients with primary Sjögren's syndrome. *J Hematol Oncol* 2017;10:90.

16.- Chiu YH, Chung CH, Lin KT, Lin CS, Chen JH, Chen HC et al. Predictable biomarkers of developing lymphoma in patients with Sjögren's syndrome: A nationwide population-based cohort study. *Oncotarget* 2017 25;8:50098-50108.

17.-De Vita S, Gandolfo S, Zandonella S, Zabotti A, Quartuccio L. The evaluation of disease activity in Sjögren's syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study. *Clin Exp Rheumatol* 2018; 36 Suppl 112(3):1501-1556.

18.- Kang J, Kim H, Kim J, Choi S, Jung SY, Jang EJ, et al. Risk of malignancy in Korean patients with primary Sjögren's syndrome. *Int J Rheum Dis* 2020;23:1240-1247.

19.- Vasaitis L, Nordmark G, Theander E, Backlin C, Smedby K, Askling J et al. Comparison of patients with and without pre-existing lymphoma at diagnosis of primary Sjögren's syndrome. *Scand J Rheumatol* 2019;48:207-212.

20.- Vasaitis L, Nordmark G, Theander E, Backlin C, Smedby KE, Asklin J, et al. Population-based study of patients with primary Sjögren's syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences. *Scand J Rheumatol* 2020; 49:225-232.

21.- Brito-Zerón P, Acar-Denizli N, Zeher M, Rasmussen A, Seror R, Theander E, et al. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. *Ann Rheum Dis* 2017;76:1042-1050.

22.- Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander E, Carsons S, et al. Classification criteria for Sjögren's syndrome: a revised version of the

European criteria proposed by the American-European Consensus. *Ann Rheum Dis* 2002; 61:554-8.

23.-Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. *Arthritis Rheumatol* 2017;69:35-45.

24.- Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). *Ann Rheum Dis* 2016; 75:382-9.

25.- Swerdlow SH, Campo E, Pileri SA, Lee Harris N, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood* 2016;127:2375-2390.

26.-Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016; 127:2391-2405.

27.- Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. *Blood* 2016;127:2082-2092.

28.-Zhang W, Sheng S, Yan S, Zhao Y, Li M, Sun J, et al. Incidence of malignancy in primary Sjögren's syndrome in a Chinese cohort. *Rheumatology* 2009;49: 571-577.

29.- Liang Y, Yang Z, Quin B, Zhong R. Primary Sjögren's syndrome and malignancy risk; a systematic review and meta-analysis. *Ann Rheum Dis* 2014; 73:1151-1156.

30.- Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. *Ann Intern Med* 1978;89:888-892.

31.- Abrol E, González-Pulido C, Praena-Fernández JM, Isenberg D. A retrospective study of long-term outcomes in 152 patients with primary Sjögren's syndrome: 25-year experience. *Clin Med* 2014;14:157-164.

32.- Nocturne G, Mariette X. Sjögren's syndrome associated lymphomas : an update on pathogenesis and management . *Br J Haematol* 2015;168:317-327.

33.-Theander E, Manthorpe R, Jacobson L. Mortality and causes of death in primary Sjögren's syndrome: A prospective cohort study. *Arthritis Rheum* 2004; 50:1262-1269.

34.- Smedby K, Vajdic C, Falster M, Engels E, Martínez-Maza O, Turner J et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. *Blood* 2008;111:4029-4037.

35.- Barsouk A, Saginla K, Anand S, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin's Lymphoma. *Med Sci* 2021;9:5.

36.- Lumish M, Falchi L, Imber BS, Scordo M, von Keudell G, Joffe E. How to treat mature B-cell neoplasm (indolent B-cell lymphomas). *J Hematol Oncol* 2021;14:5.

37- Müller Am, Ihorst G, Mertelsmann R, Engerlhardt M. Epidemiology of non-Hodgkin´s lymphoma (NHL): trends, geographic distribution, and etiology. *Ann Hematol* 2005;84:1-12.

38.- Cerhan JR, Habermann TM. Epidemiology of Marginal Zone Lymphoma. *Ann Lymphoma* 2021 published on 20 March 2021. doi: 10.21037/aol-20-28

39.- Nakamura S, Ponzoni M. Marginal zone B-cell lymphoma: lesson from Western and Eastern diagnostic approaches. *Pathology* 2020;52:15-29.

40.- Goules A, Argyropoulou O, Pezoulas V, Chatzis L, Critselis E, Gandolfo S,et al. Primary Sjögren's syndrome of early and late onset: distinct clinical phenotypes and lymphoma development. *Front Immunol* 2020;11:594096.

41.- Gorodetskiy V, Probatova N, Vasilyev V. Characteristic of diffuse B cell-lymphoma in patients with primary Sjögren's syndrome. *Int J Rheum Dis* 2020;23: 540-8.

42.- Feinstein AJ, Ciarleglio MM, Cong X, Otremba MD, Judson.Parotid gland lymphoma: prognostic analysis of 2140 patients. *Laryngoscope* 2013;123:1199-1203.

43.- The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. *N Engl J Med* 1993; 29:987-94.

Table 1. Characterization and outcomes of hematological malignancy in 414 patients with primary SS

Epidemiology (n=414)	N	%
Gender (women)	355	85.7
Ethnicity (white)	368	88.8
Age at SS diagnosis (mean, range)	52.4 years	10-87 years
Age at diagnosis of hematologic malignancy (mean, range)	57.2 years	21-91 years
Timing of diagnosis of hematologic malignancy		
Before SS diagnosis	43	10.1
Concomitant/after SS diagnosis	371	89.7
WHO Classification (n=414)		
Mature B cell neoplasia	376	90.8
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)	197	47.5
Diffuse large B-cell lymphoma (DLBCL)	67	16.2
Nodal marginal zone lymphoma	29	7.0
Chronic lymphocytic leukemia/small lymphocytic lymphoma	19	4.5
Follicular lymphoma	17	4.1
Other	37	8.9
NHL not classifiable (insufficient data for WHO class)	13	3.1
Myeloid neoplasias and acute leukemias	20	4.8
Hodgkin lymphoma	10	2.4
Mature T and NK neoplasia	8	1.9
Primary organ specific confirmation (386 patients)		
Exocrine glands (salivary, lachrymal)	176	45.3
Lymph nodes[a]	92	23.8
Bone marrow (only biopsed organ)	39	10.1
Digestive	25	6.4
ENT	12	3.1
Lungs	11	3.6
Peripheral blood	10	2.5
Spleen	5	1.2
Skin	6	1.5
Eye	3	0.7
Soft tissue/muscular	2	0.5
Thymus	3	0.7
Central nervous system	1	0.2

Kidney	1	0.2
First-line therapeutic approach (364 patients)		
Immunochemotherapy[b]	129	35.4
Chemotherapy alone[c]	58	15.9
Immunotherapy alone[d]	43	11.8
Other therapeutic interventions[e]	86	23.6
No therapeutic intervention (“watch and wait”)	48	13.1
Malignancy outcomes		
First-line treatment response (281 patients)		
Complete response	225	80
Partial response	38	13.5
No response	18	6.4
Relapse (n=263)	90	34.2
Death (n=365)	47	12.8
Causes of death (n=39)		
Cardiovascular	2	5.1
Infection	12	30.7
Hematologic malignancy progression	20	51.2
Other causes	5	12.8

[a] Lymph nodes: Inguinal 13 (14.1%), abdominal 6 (6.5%), axilar 7 (7.6%), cervical 30 (32.6%), mediastinal 5 (5.4%), retroperitoneal 2 (21.1%), non-specified 29 (31.5%)

[b] Immunochemotheraphy

Main regimens: R-CHOP (n=67), RTX-CFM (n=11), R-CVP (n=10), RTX+chlorambucil (n=8)

[c] Chemotherpay alone

Main regimens: CHOP (n=19), BR (n=15), other (n=21)

[d] Immunotherapy alone

Main regimen: RTX (n=43)

[e] Including surgery and/or radiotherapy alone (n=65), autologous transplantation (n=5), only steroids (n=6), only intrathecal chemotherapy (n=1), intravenous immunoglobulins (n=1), others (n=8).

Table 2. Comparison of the main mature B cell lymphoma subtypes

Variables	Mature B cells (main subtypes)					P
	MALT [a] lymphoma (n=197)	Nodal MZL[b] (n=29)	DLBCL[c] (n=67)	CLL/SLL[d] (n=19)	FL[e] (n=17)	
Epidemiological features						
Gender (female)	171 (86.8)	26 (89.7)	56 (83.6)	18 (94.7)	13 (76.5)	0.513
Age (mean, years)	49.2 ± 13.0	54.3 ± 14.3	53.3 ± 13.8	59.9 ± 15.1	56.2 ± 12.1	0.002
Time of follow-up after lymphoma diagnosis (years)	8.7 ± 6.6	6.8 ± 5.0	6.3 ± 5.7	6.9 ± 5.6	13 ± 8.4	0.004
Timing of diagnosis						
Lymphoma diagnosed concomitant/after SS	185 (93.9)	28 (96.6)	64 (95.5)	15 (78.9)	14 (82.4)	0.037
Clinical features at presentation						
Constitutional symptoms	44/173 (25.4)	10 (34.5)	33/62 (53.2)	2/15 (13.3)	7/16 (43.8)	0.001
Glandular enlargement	137/174 (78.7)	10 (34.5)	10/62 (16.1)	2/15 (13.3)	3/16 (18.8)	<0.001
Peripheral lymphadenopathy	22/173 (12.7)	15 (51.7)	32/62 (51.6)	3/15 (20.0)	8/16 (50.0)	<0.001
Incidental diagnosis	2/174 (1.1)	0 (0)	1/62 (1.6)	7/15 (46.7)	0/16 (0)	<0.001
Outcomes						
Complete response	136/148 (91.9)	17/20 (85.0)	36/52 (69.2)	1/3 (33.3)	6/9 (66.7)	<0.001
Relapse	45/146 (30.8)	11/20 (55.0)	14/46 (30.4)	1/2 (50.0)	5/9 (55.6)	0.140
Death	7/181 (3.9)	3/26 (11.5)	17/57 (29.8)	2/16 (12.5)	0/13 (0)	<0.001
Total ESSDAI[f]	19.0 ± 5.5	18.0 ± 5.6	18.1 ± 6.2	15.3 ± 4.3	15.3 ± 4.3	0.061
ESSDAI domains [g]	n=185	n=28	n=64	n=15	n=14	
Constitutional	27 (14.6)	10(35.7)	27 (42.2)	2 (13.3)	4 (28.6)	<0.001
Lymphadenopathy	185 (100)	28 (100)	64 (100)	15 (100)	14 (100)	1,000
Glandular	137 (78.7)	9 (32.1)	13 (20.3)	4 (26.7)	3 (21.4)	<0.001
Articular	29 (15.7)	5 (17.9)	5 (7.8)	0 (0)	3 (21.4)	0.201
Cutaneous	15 (8.1)	5 (17.9)	4 (6.2)	1 (6.7)	0 (0)	0.276
Pulmonary	3 (1.6)	1 (3.6)	2(3.1)	0 (0)	0 (0)	0.823
Renal	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1,000
Muscular	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1,000
PNS	15 (8.1)	0 (0)	4 (6.2)	0 (0)	0 (0)	0.296
Central nervous system	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1000
Haematological	48 (25.9)	7 (25)	19 (29.7)	2(13.3)	5 (35.7)	0.673
Biological	108 (58.4)	14(50)	26 (40.6)	4 (26.7)	5 (35.7)	0.020

[a] MALT: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, [b] MZL: Marginal zone lymphoma, [c] DLBCL: Diffuse large B-cell lymphoma, [d] CLL/SLL:chronic lymphocytic leukemia/small lymphocytic lymphoma, [e] FL: Follicular cell lymphoma

[f] Disease activity at the time of lymphoma diagnosis. 43 patients with neoplasia before SS diagnosis were excluded (n=371). [g] Level of activity is recorded as no versus any type of activity (low/moderate/high) in the analysis.

Table 3. Comparison of salivary vs. extrasalivary gland lymphomas

Variables	Salivary glands n=168	Extra-salivary sites n=77	P	Unadjusted OR 95% CI	Adjusted OR 95% CI
Epidemiological features					
Gender (female)	144 (85.7)	67 (87.0)	0.941	0.90 [0.39-1.93]	0.86 [0.37-1.87]
Age (mean, years)	48.5 ± 12.4	53.0 ± 13.9	0.016	0.97 [0.95-0.99]	0.97 [0.95-0.99]
Time of follow-up after lymphoma diagnosis (years)	8.1 ± 5.7	8.9 ± 8.1	0.467	0.98 [0.94-1.03]	0.98 [0.93-1.02]
Timing of diagnosis. Lymphoma concurrent/after SS diagnosis	158 (94.0)	66 (85.7)	0.055	2.63 [1.06-6.61]	2.27 [0.90-5.79]
Clinical features					
Constitutional symptoms	33/155 (21.3)	20/70 (28.6)	0.307	0.68 [0.36-1.30]	0.67 [0.35-1.30]
Peripheral lymphadenopathy	17/155 (11.0)	8/70 (11.4)	1,000	0.95 [0.40-2.45]	0.88 [0.36-2.28]
Incidental diagnosis	0/155 (0)	3/70 (4.3)	0.049	-	-
Mature B cells types					
MALT lymphoma[a]	144 (85.7)	34 (44.2)	<0.001	7.59 [4.11-14.36]	7.45 [3.99-14.29]
Nodal MZL[b]	9 (5.4)	7 (9.1)	0.412	0.57 [0.20-1.64]	0.62 [0.22-1.81]
DLBCL[c]	6 (3.6)	21 (27.3)	<0.001	0.10 [0.03-0.24]	0.10 [0.03-0.25]
CLL/SLL[d]	2 (1.2)	3 (3.9)	0.366	0.30 [0.04-1.83]	0.28 [0.03-1.78]
FL[e]	3 (1.8)	2 (2.6)	1,000	0.68 [0.11-5.26]	0.60 [0.09-4.86]
Outcomes					
Complete response	118/12 (93.7)	46/62 (74.2)	<0.001	5.13 [2.11-13.43]	4.28 [1.71-11.42]
Relapse	38/125 (30.4)	21/57 (36.8)	0.490	0.75 [0.39-1.46]	0.79 [0.41-1.57]
Death	4/154 (2.6)	12/66 (18.2)	<0.001	0.12 [0.03-0.36]	0.15 [0.04-0.46]

[a] MALT: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, [b] MZL: Marginal zone lymphoma, [c] DLBCL: Diffuse large B-cell lymphoma, [d] CLL/SLL:chronic lymphocytic leukemia/small lymphocytic lymphoma, [e] FL: Follicular cell lymphoma

Table 4. Comparison of hematological malignancy according to timing presentation.

Variables	Timing		*P*	Unadjusted OR [95% CI]	Adjusted OR [f] [95% CI]
	Prior to SS diagnosis (n=43)	**Concurrent/after SS diagnosis (n=371)**			
Epidemiological features					
Gender (female)	41 (95.3)	314 (84.6)	0.095	3.72 [1.1-23.23]	3.92 [1.15-24.65]
Age (mean, years)	60.0 ± 12.8	51.5 ± 13.6	<0.001	1.05 [1.02-1.08]	1.05 [1.02-1.08]
Time of follow-up (years)	15.5 ± 8.8	7.1 ± 5.8	<0.001	1.16 [1.11-1.21]	1.20 [1.13-1.27]
Clinical features					
Constitutional symptoms	6/33 (18.2)	120/337 (35.6)	0.068	0.40 [0.15-0.94]	0.39 [0.14-0.93]
Glandular enlargement	11/33 (33.3)	157/338 (46.4)	0.207	0.58 [0.26-1.20]	0.80 [0.35-1.76]
Peripheral lymphadenopathy	9/33 (27.3)	100/337 (29.7)	0.929	0.89 [0.38-1.92]	0.79 [0.33-1.75]
Incidental diagnosis	7/33 (21.2)	25/338 (7.4)	0.018	3.37 [1.25-8.21]	2.47 [0.88-6.24]
WHO main groups (B)	34 (79.1)	342 (92.2)	0.011	0.32 [0.14-0.77]	0.35 [0.15-0.88]
Mature B cells types					
MALT lymphoma[a]	12 (27.9)	185 (49.9)	0.010	0.39 [0.19-0.76]	0.48 [0.23-0.97]
Nodal MZL[b]	1 (2.3)	28 (7.5)	0.340	0.29 [0.02-1.42]	0.25 [0.01-1.27]
DLBCL[c]	3 (7.0)	64 (17.3)	0.130	0.36 [0.09-1.03]	0.33 [0.08-0.97]
CLL/SLL[d]	4 (9.3)	15 (4.0)	0.240	2.43 [0.67-7.10]	1.61 [0.42-4.97]
FL[e]	3 (7.0)	14 (3.8)	0.551	1.91 [0.43-6.17]	1.89 [0.41-6.37]
Outcomes					
Complete response	27/29 (93.1)	198/252 (78.6)	0.107	3.68 [1.06-23.28]	4.48 [1.22-29.03]
Relapse	11/29 (37.9)	79/234 (33.8)	0.811	1.20 [0.53-2.63]	1.13 [0.48-2.53]
Death	1/40 (2.5)	46/325 (14.2)	0.068	0.16 [0.01-0.74]	0.12 [0.01-0.57]

[a] MALT: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, [b] MZL: Marginal zone lymphoma, [c] DLBCL: Diffuse large B-cell lymphoma, [d] CLL/SLL:chronic lymphocytic leukemia/small lymphocytic lymphoma, [e] FL: Follicular cell lymphoma.

[f] Adjusted OR by sex and age at diagnosis

Table 5. Comparison of clinical and serological features among patients with and without hematological malignancy

Variables	Patients with hematological malignancy[a] (n = 371)	Age-sex matched controls [b] (n=742)	*P*
Age at diagnosis of SjS (mean)	52.1 ± 13.5	52.0 ± 13.6	0.965
Sex (woman)	315 (84.9)	630 (84.9)	1,000
Disease duration, years	11.7 ± 7.7	11.3 ± 7.6	0.897
Ethnicity			0.258
White	331 (89.2)	631/740 (85.3)	
Hispanic	20 (5.4)	43/740 (5.8)	
Black african-american	5 (1.3)	12/740 (1.6)	
Asian	15 (4)	52/740 (7)	
Others	0 (0)	2/740 (0.3)	
Dry eye	351 (94.6)	690 (93)	0.366
Dry mouth	363 (97.8)	689 (92.9)	0.001
Altered ocular tests	274/298 (91.9)	539/623 (86.5)	0.022
Abnormal oral tests	254/271 (93.7)	442/549 (80.5)	<0.001
Positive salivary gland biopsy	231/252 (91.7)	488/547 (89.2)	0.344
Antinuclear antibodies+	326/363 (89.8)	612/721 (84.9)	0.032
Rheumatoid factor+	210/339 (61.9)	338/686 (49.3)	<0.001
Anti-Ro/SS-A+	301/366 (82.2)	525/729 (72)	<0.001
Anti-La/SS-B+	201/365 (55.1)	319/723 (44.1)	0.001
Cryoglobulins+	68/239 (28.5)	40/405 (9.9)	<0.001
Low C3 levels (<0.82 g/L)	79/301 (26.2)	87/633 (13.7)	<0.001
Low C4 levels (<0.11 g/L)	87/294 (29.6)	93/633 (14.7)	<0.001
Baseline ESSDAI	13.2 ± 12.6	7.0 ± 8.3	<0.001
Baseline DAS			<0.001
Low	98/323 (30.3)	358/707 (50.6)	
Moderate	96/323 (29.7)	234/707 (33.1)	
High	129/323 (39.9)	115/707 (16.3)	
ESSDAI domains[c]			
Constitutional	72/336 (21.4)	77/707 (10.9)	<0.001
Lymphadenopathy	148/336 (44)	75/707 (10.6)	<0.001
Glandular	153/336 (45.5)	156/707 (22.1)	<0.001
Articular	116/336 (34.5)	305/707 (43.1)	0.010
Cutaneous	47/336 (14)	83/707 (11.7)	0.354
Pulmonary	42/336 (12.5)	81/707 (11.5)	0.700
Renal	17/336 (5.1)	29/707 (4.1)	0.587
Muscular	11/336 (3.3)	18/707 (2.5)	0.641
PNS	38/336 (11.3)	54/707 (7.6)	0.066
CNS	5/336 (1.5)	23/707 (3.3)	0.149
Haematological	134/329 (40.7)	168/690 (24.3)	<0.001
Biological	233/325 (71.7)	352/646 (54.5)	<0.001

[a] Level of activity is recoded as no versus any type of activity (low/moderate/high) in the analysis.
[b] Age, sex and disease duration matched SS patients without lymphoma.
[c] 43 patients with neoplasia before SS diagnosis were excluded (n=371).

Figure Legend 1. Distribution of extranodal involvement by organ.

Figure Legend 2. Disease-specific survival among patients with malignancy. (A) Kaplan-Meir survival curve being free of death in the overall cohort. (B) Kaplan-Meier survival curve according to the 5 main subtypes of mature B-cell hematological malignancy. (C) Kaplan-Meier survival curve according to salivary vs extrasalivary involvement. (D) Kaplan- Meier survival curve according to timing presentation.